Epigenetic Aging Biomarker May Predict Depression
A simple blood test that tracks how fast white blood cells age could soon help detect depression. Researchers published this discovery in The Journals of Gerontology, Series A. Their work brings scientists closer to an objective biomarker for depression — a condition that affects nearly one in five adults in the United States. Furthermore, it signals a new era for precision mental health care.
What Is Epigenetic Aging?
Biological age does not always match a person’s chronological age. Scientists use algorithms called epigenetic clocks to measure this gap. These tools detect chemical changes to DNA — specifically, the addition of methyl groups at sites called CpG sites. Notably, these patterns shift over time and reveal how quickly a person’s cells are aging.
This process, known as DNA methylation (DNAm), records biological stress, lifestyle factors, and disease history. Consequently, a person’s biological age can run ahead of their actual age — a state called epigenetic age acceleration (EAA). Researchers now link EAA closely to serious health outcomes, including depression.
How the Research Was Conducted
Study Design and Participants
The research team analyzed data from 440 women. Of these, 261 had HIV and 179 did not. All participants belonged to the Women’s Interagency HIV Study, a long-running cohort that tracks health outcomes in diverse female populations.
Researchers measured depression using the Center for Epidemiologic Studies Depression Scale (CES-D) — a 20-item questionnaire. This tool captures both physical (somatic) and emotional (non-somatic) symptoms of depression. Accordingly, it provided a broad view of how depression manifests in each participant.
Tools Used to Measure Biological Aging
The team applied two epigenetic clocks to blood samples. The first clock measured aging across multiple cells and tissue types. The second focused specifically on monocytes — a type of white blood cell. This dual approach allowed researchers to compare the predictive power of each clock for depression outcomes.
Key Findings — Monocytes and Mood
Results showed that monocyte aging was a sensitive biomarker for non-somatic symptoms of depression. Specifically, it predicted anhedonia (loss of pleasure), hopelessness, and feelings of failure. Notably, this connection held true for both women with HIV and those without.
By contrast, the broader multi-tissue clock did not show the same association. This suggests that monocyte-specific aging carries unique information about emotional and cognitive aspects of depression. Additionally, monocytes already have a known role in depression — research consistently shows elevated monocyte levels in people with the condition.
Understanding Non-Somatic Depression Symptoms
Depression symptoms fall into two broad categories. Somatic symptoms include fatigue, sleep problems, and appetite changes. Non-somatic symptoms, on the other hand, are emotional and cognitive — such as hopelessness, worthlessness, and difficulty concentrating.
Traditionally, clinicians rely on self-reported questionnaires to assess these symptoms. As a result, diagnosis often remains subjective. Therefore, a biological marker for non-somatic symptoms represents a significant step forward. It adds an objective layer to a process that has long depended entirely on patient self-reporting.
What This Means for Mental Health Care
Lead researcher Nicole Beaulieu Perez envisions a meaningful future for this work. She references the principle: “What gets measured gets managed.” In practice, this means combining patient experience with objective biological data to guide treatment decisions.
Today, treating depression often involves trial and error. Doctors try one medication and then switch if it fails. However, a biological test could change this approach entirely. Moreover, it could help clinicians predict which treatment will suit a specific patient before they even start. Earlier diagnosis — before symptoms worsen — becomes a genuine possibility.
The Road Ahead for Precision Psychiatry
Perez acknowledges that more research is necessary before this biomarker enters clinical practice. The current study focused on women, including a high proportion of HIV-positive participants. Therefore, future studies must broaden the sample to include men and diverse age groups.
Nevertheless, this research adds an important building block for precision mental health care. The goal is to create a biological framework that guides both diagnosis and treatment. High-risk populations — such as those living with HIV — may benefit most in the near term.
In summary, the link between monocyte epigenetic aging and non-somatic depression symptoms marks a meaningful scientific advance. Furthermore, it opens the door to blood-based testing that could transform how clinicians detect and treat one of the world’s most common mental health conditions.
